Combination therapy with controlled-release CNP agonists
The present invention relates to a combination of a CNP agonist and at least one further biologically active moiety or drug for use in a method for the treatment or prevention of disorders that benefit from stimulating growth, pharmaceutical compositions comprising at least one CNP agonist, preferably controlled-release CNP agonist, wherein the pharmaceutical composition comprises at least one further biologically active moiety or drug, to using these pharmaceutical compositions as a medicament, to their use in the treatment of disorders that benefit from stimulating growth and to methods of preventing or treating a patient having a disorder that benefits from stimulating growth.
1. A pharmaceutical composition comprising at least one controlled-release CNP agonist;
wherein the pharmaceutical composition comprises at least one further biologically active moiety or drug;
wherein the at least one further biologically active moiety or drug is human growth hormone;
wherein the controlled-release CNP agonist releases at least one CNP agonist, the CNP agonist being CNP under physiological conditions with a release half-life of at least 6 hours, wherein the controlled-release CNP agonist is a compound of formula (IIf):
or a pharmaceutically acceptable salt thereof;
wherein
the unmarked dashed line indicates the attachment to a nitrogen provided by the side-chain of the lysine at position 26 of a CNP moiety of SEQ ID NO:24 by forming an amide bond; and
the dashed line marked with the asterisk indicates attachment to —Z having the structure
wherein
each —Z a is
wherein
each c1 is an integer independently ranging from 200 to 250; and
wherein the composition is administrable to a patient with a disorder that benefits from stimulating growth to result in a synergistic increase in bone growth from the combination of the controlled-release CNP agonist and human growth hormone.
2. The pharmaceutical composition of claim 1 , wherein the at least one further biologically active moiety or drug is a drug in its free form.
3. The pharmaceutical composition of claim 1 , wherein the at least one further biologically active moiety or drug is in the form of a stable conjugate.
4. The pharmaceutical composition of claim 1 , wherein the at least one further biologically active moiety or drug is in the form of a controlled-release compound.
5. The pharmaceutical composition claim 1 , wherein the controlled-release CNP agonist and the at least one further biologically active moiety or drug are formulated for simultaneous, separate or sequential administration.
6. The pharmaceutical composition of claim 1 , wherein the controlled-release CNP agonist is water-insoluble.
7. The pharmaceutical composition of claim 1 , wherein the at least one further biologically active moiety or drug is of formula (A1)
wherein each n = 200-250.